Prognostic Value of TP53 Gene Mutations in Higher Risk MDS Treated with Azacitidine

被引：0
|
作者：
Bally, Cecile [1 ]
Ades, Lionel [2 ]
Renneville, Aline [3 ]
Preudhomme, Claude [4 ]
Mozziconacci, Marie-Joelle [5 ]
de The, Hugues [6 ]
Lehmann-Che, Jacqueline [6 ]
Fenaux, Pierre [2 ]
机构：
[1] Hop Avicenne, Hematol Clin, F-93009 Bobigny, France
[2] Univ Paris 13, Hop Avicenne, AP HP, Dept Hematol, Paris, France
[3] CHRU Lille, Ctr Biol Pathol, Lab Hematol, Lille, France
[4] Univ Lille, CHRU Lille, Lille, France
[5] Inst J Paoli I Calmettes, Lab Mol Biol & Cytogenet, F-13009 Marseille, France
[6] Univ Paris, Hosp St Louis, F-75252 Paris, France
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.1706.1706
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1706
引用
收藏
页数：2
相关论文
共 50 条
  • [31] TP53 gene mutations in canine osteosarcoma
    Kirpensteijn, Jolle
    Kik, Marja
    Teske, Erik
    Rutteman, Gerard R.
    VETERINARY SURGERY, 2008, 37 (05) : 454 - 460
  • [32] Three germline mutations in the TP53 gene
    Cornelis, RS
    vanVliet, M
    vandeVijver, MJ
    Vasen, HFA
    Voute, PA
    Top, B
    Khan, PM
    Devilee, P
    Cornelisse, CJ
    HUMAN MUTATION, 1997, 9 (02) : 157 - 163
  • [33] Prognostic value genotypes and LOH at TP53 codon 72 and TP53mutations in primary breast cancer
    M Kyndi
    J Alsner
    LL Hansen
    FB Sørensen
    J Overgaard
    Breast Cancer Research, 7
  • [34] Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutations
    Ciurea, Stefan O.
    Chilkulwar, Abhishek
    Saliba, Rima M.
    Chen, Julianne
    Rondon, Gabriela
    Patel, Keyur P.
    Khogeer, Haitham
    Shah, Abdul R.
    Randolph, Brion V.
    Perez, Jorge M. Ramos
    Popat, Uday
    Hosing, Chitra M.
    Bashir, Qaiser
    Mehta, Rohtesh
    Al-Atrash, Gheath
    Im, Jin
    Khouri, Issa F.
    Kebriaei, Partow
    Champlin, Richard E.
    BLOOD, 2018, 131 (26) : 2989 - 2992
  • [35] Is TP53 Mutated AML the Same Disease as TP53 Mutated MDS?
    Valk, Peter J. M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S3 - S5
  • [36] Prognostic value of KRAS mutations, TP53 mutations and PD-L1 expression among lung adenocarcinomas treated with immunotherapy
    Tonnesen, Ea Maria Tonning
    Stougaard, Magnus
    Meldgaard, Peter
    Lade-Keller, Johanne
    JOURNAL OF CLINICAL PATHOLOGY, 2024, 77 (01) : 54 - 60
  • [37] THERAPY OF TP53 MUT MDS
    Sallman, D.
    LEUKEMIA RESEARCH, 2023, 128
  • [38] TP53 Mutations Negatively Impact Survival of Acute Myeloid Leukemia Patients Treated with Standard Doses of Azacitidine
    Bories, Pierre
    Prade, Nais
    Lagarde, Stephanie
    Cabarrou, Bastien
    Plenecassagnes, Julien
    Luquet, Isabelle
    De Mas, Veronique
    Filleron, Thomas
    Cassou, Manon
    Sarry, Audrey
    Fornecker, Luc Matthieu
    Simand, Celestine
    Bertoli, Sarah
    Gronemeyer, Hinrich
    Recher, Christian
    Delabesse, Eric
    BLOOD, 2018, 132
  • [39] TP53 GENE MUTATIONS IN PROSTATE CANCER PROGRESSION
    Ecke, Th. H.
    Schlechte, H. H.
    Schiemenz, K.
    Sachs, M. D.
    Lenk, S. V.
    Rudolph, B. D.
    Loening, S. A.
    ANTICANCER RESEARCH, 2008, 28 (6B) : 4055 - 4056
  • [40] Germline mutations of TP53 gene in breast cancer
    Damineni, Surekha
    Rao, Vadlamudi Raghavendra
    Kumar, Satish
    Ravuri, Rajasekar Reddy
    Kagitha, Sailaja
    Dunna, Nageswara Rao
    Digumarthi, Raghunadharao
    Satti, Vishnupriya
    TUMOR BIOLOGY, 2014, 35 (09) : 9219 - 9227
12345